"Reduced Dosage Burden, 43.9% LDL Cholesterol Reduction"

On June 1, Daewoong Pharmaceutical announced that it had successfully concluded a month-long launch symposium tour for its new combination drug for dyslipidemia, Barojet (pitavastatin 1mg and ezetimibe 10mg), which took place in Busan, Gyeongju, and Seoul beginning in April this year.


The symposium was organized to present the clinical phase 3 results and clinical value of Barojet, which was launched in April, to healthcare professionals, and to share treatment strategies within Daewoong Pharmaceutical’s portfolio of combination drugs for dyslipidemia that can be applied across diverse patient groups. The events were held in succession at Grand Chosun Busan, Lahan Select Gyeongju, and Dragon City Seoul, drawing a total of 210 healthcare professionals from across the country and generating strong interest.

Daewoong Pharmaceutical's combination drug for dyslipidemia treatment, Barojet. Daewoong Pharmaceutical

Daewoong Pharmaceutical's combination drug for dyslipidemia treatment, Barojet. Daewoong Pharmaceutical

View original image

The symposium focused on tailored treatment strategies for various patient groups encountered in real-world clinical settings. Intensive discussions took place on how to utilize Daewoong Pharmaceutical’s combination product portfolio based on patient characteristics, such as patients ranging from low and moderate risk to very high risk, those with atherosclerotic cardiovascular disease (ASCVD) and chronic kidney disease (CKD), as well as patients with mixed dyslipidemia.


The Barojet session highlighted low and moderate risk patients, who comprise over 70% of the adult population in Korea, as the main target group. In particular, it was emphasized that among patients with prediabetes or metabolic diseases, cardiovascular risk can increase early, making stable LDL cholesterol (LDL-C) management from the outset especially important.


The phase 3 clinical results for Barojet were also unveiled. In a study involving 129 Korean patients with primary hypercholesterolemia, Barojet reduced LDL-C by 43.9% at week 8, demonstrating a stronger lipid-lowering effect compared to pitavastatin 1mg monotherapy (29.1%).


Pitavastatin, the main component of Barojet, was introduced as an agent with a low risk of drug-drug interactions via CYP enzyme pathways, making it relatively safe for patients on multiple medications. It was also highlighted that, compared with other statins, pitavastatin is associated with a lower risk of new-onset diabetes, thereby reducing the burden of blood sugar management. Based on these findings, Barojet was presented as a treatment option that supports both achievement of LDL-C targets and long-term medication adherence.


The session for high-risk patients discussed more intensive LDL-C lowering strategies. For those with atherosclerotic cardiovascular disease (ASCVD) and acute coronary syndrome (ACS), the importance of rapidly reaching and maintaining LDL-C goals was emphasized, and the combination drug rosuvastatin and ezetimibe (Crezet) was introduced as a major treatment option. For high-risk patients with impaired renal function, such as those with chronic kidney disease (CKD), the potential clinical use of the atorvastatin-based combination drug Litovazet, which has low renal excretion dependence, was discussed.

Scene from the Barojet Launch Symposium held at Busan Grand Josun Hotel. Daewoong Pharmaceutical

Scene from the Barojet Launch Symposium held at Busan Grand Josun Hotel. Daewoong Pharmaceutical

View original image

The session on patients with mixed dyslipidemia highlighted the importance of managing residual cardiovascular risk even after LDL-C control. For patients with both hypertriglyceridemia and abnormal HDL-C, the pitavastatin and fenofibrate combination drug Baropeno was introduced as a treatment strategy, offering the potential to lower triglycerides and improve HDL-C in addition to LDL-C reduction.


This symposium was evaluated as an opportunity to present both patient group-specific treatment strategies and the use of combination therapies based on clinical evidence for Barojet, thereby enhancing the practical applicability of these options in actual clinical settings. The event also featured active Q&A sessions about treatment approaches and drug selection criteria tailored to patient characteristics.


Meanwhile, Daewoong Pharmaceutical is strengthening its dyslipidemia combination drug portfolio and operates the digital platform 'Wellcheck' to support primary care clinics in the 'Primary Care Chronic Disease Management Program.' Wellcheck is a platform that assists in everything from patient identification to medication and lifestyle management. By integrating treatments and digital solutions, Daewoong Pharmaceutical plans to offer a 'total solution' to enhance continuity in chronic disease management.



Hyungcheol Park, Head of ETC Marketing Division at Daewoong Pharmaceutical, stated, "Barojet offers an effective LDL-C management solution for low and moderate risk patients, while also considering long-term adherence. Daewoong Pharmaceutical will continue to share evidence-based dyslipidemia treatment strategies tailored to specific patient groups to provide highly practical treatment options in real-world clinical practice."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing